MET-PET/CT技术诊断MRI疑诊脑胶质瘤及评估恶性增殖行为价值

doi:10.7517/issn.1674-0475.210312

摘要/Abstract

摘要： 选取91例经磁共振成像（MRI）检查后疑诊为脑胶质瘤患者作为研究对象，均行病理检查。以病理检查结果为准，¹¹C-蛋氨酸正电子发射断层显像术（MET-PET/CT）诊断MRI疑诊脑胶质瘤敏感度为96.72%，特异度为96.67%，准确度为96.70%；标准化摄取值（SUV）、肿瘤/正常脑组织值（T/N）与WHO脑胶质瘤分级呈正相关（P<0.05）；SUV、T/N值与Ki-67增殖指数呈正相关（P<0.05）。因此，通过MET-PET/CT技术获取SUV、T/N值不仅可无创鉴别诊断脑胶质瘤分级，还能评估脑胶质瘤细胞增殖动力、恶性生物学行为，有望成为MRI诊断脑胶质瘤的重要补充手段。

关键词: ¹¹C-蛋氨酸正电子发射断层显像术, 脑胶质瘤, 标准化摄取值, 肿瘤/正常脑组织值, 恶性生物学行为

Abstract: A total of 91 cases of patients with glioma suspected to be diagnosed as gliomas after magnetic resonance imaging (MRI) examinations were selected as the research objects. All patients underwent pathological examinations. The sensitivity, specificity and accuracy of ¹¹C-methionine positron emission tomography (MET-PET/CT) technique in the diagnosis of MRI suspected gliomas were 96.72%, 96.67%, and 96.70%, respectively, based on the pathological examination results. The standardized uptake value (SUV) and tumor/normal brain tissue ratio (T/N) were positively correlated with the WHO glioma grade (P<0.05). SUV value, T/N value and Ki-67 proliferation index were positively correlated (P<0.05). It is suggested that the SUV value and T/N value obtained by MET-PET/CT technology can not only non-invasively differentiate the grading of glioma, but also assess the proliferation dynamics and malignant biological behavior of glioma cells. It is expected to become an important supplementary method for MRI diagnosis of glioma.

Key words: ¹¹C-methionine positron emission tomography technique, glioma, standardized uptake value, tumor/normal brain tissue ratio, malignant biological behavior

韦琳, 唐武儒, 廖云, 韦晶晶, 陆泳梁. MET-PET/CT技术诊断MRI疑诊脑胶质瘤及评估恶性增殖行为价值[J]. 影像科学与光化学, 2021, 39(5): 716-720.

WEI Lin, TANG Wuru, LIAO Yun, WEI Jingjing, LU Yongliang. The Value of MET-PET/CT in the Diagnosis of MRI Suspected Glioma and the Evaluation of Malignant Proliferative Behavior[J]. IMAGING SCIENCE AND PHOTOCHEMISTRY, 2021, 39(5): 716-720.

参考文献

[1] 刘臣, 李根华, 李想, 等. 脑胶质瘤综合治疗的研究进展[J]. 中国微侵袭神经外科杂志, 2019, 24(4):182-185.
[2] Aslan K, Gunbey H P, Tomak L, et al. Multiparametric MRI in differentiating solitary brain metastasis from high-grade glioma:Diagnostic value of the combined use of diffusion-weighted imaging, dynamic susceptibility contrast imaging, and magnetic resonance spectroscopy parameters[J]. Neurologia i Neurochirurgia Polska, 2019, 53(3):227-237.
[3] Tsiouris S, Bougias C, Fotopoulos A. Principles and current trends in the correlative evaluation of glioma with advanced MRI techniques and PET[J]. Hellenic Journal of Nuclear Medicine, 2019, 22(3):206-219.
[4] Mitamura K, Yamamoto Y, Norikane T, et al. Correlation of ¹⁸F-FDG and ¹¹C-methionine uptake on PET/CT with Ki-67 immunohistochemistry in newly diagnosed intracranial meningiomas[J]. Annals of Nuclear Medicine, 2018, 32(9):627-633.
[5] 李欢, 孙宇, 武玉亮, 等. ¹¹C-MET-PET/CT引导下多点转录组学分析脑干胶质瘤的细胞功能异质性[J]. 中华神经外科杂志, 2019, 35(6):581-587.
[6] 孙满意, 董海波. 体素内不相干运动扩散加权成像评估脑胶质瘤细胞增殖能力的价值[J]. 中华全科医学, 2019, 17(7):1174-1177.
[7] Bulleid L S, James Z, Lammie A, et al. The effect of the revised WHO classification on the incidence of grade II meningioma[J]. British Journal of Neurosurgery, 2020, 34(5):584-586.
[8] Almansory K O, Fraioli F. Combined PET/MRI in brain glioma imaging[J]. British Journal of Hospital Medicine (London), 2019, 80(7):380-386.
[9] Conti Nibali M, Rossi M, Sciortino T, et al. Preoperative surgical planning of glioma:limitations and reliability of fMRI and DTI tractography[J]. Journal of Neurosurgical Sciences, 2019, 63(2):127-134.
[10] Ogawa T, Kawai N, Miyake K, et al. Diagnostic value of PET/CT with ¹¹C-methionine (MET) and ¹⁸F-fluorothymidine (FLT) in newly diagnosed glioma based on the 2016 WHO classification[J]. Ejnmmi Research, 2020, 10(1):44.
[11] Kim D, Chun J H, Kim S H, et al. Re-evaluation of the diagnostic performance of ¹¹C-methionine PET/CT according to the 2016 WHO classification of cerebral gliomas[J]. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46(8):1678-1684.
[12] 龙亚丽, 何巧, 张冰, 等. ¹³N-NH₃、¹¹C-MET及¹⁸F-FDG PET/CT显像在脑胶质瘤诊断与评估中的对比研究[J]. 中华核医学与分子影像杂志, 2020, 40(3):159-165.
[13] 徐华, 彭东, 鲁龙龙. 术前MRI增强扫描对脑胶质瘤病理分级诊断及其与微血管密度的相关性[J]. 中国CT和MRI杂志, 2020, 18(2):48-50.
[14] 杨生军. ¹¹C-蛋氨酸PET/CT及整合素β1表达与胶质瘤生物学行为的相关性研究[D]. 昆明:昆明医学院, 2011.
[15] 赵晓斌, 王凯, 孔鲁, 等.¹¹C-蛋氨酸PET/CT联合MRI在弥漫内生型脑干胶质瘤诊断和预后评估中的作用[J]. 中华神经外科杂志, 2019, 35(9):914-918.
[16] Qiao Z, Zhao X, Wang K, et al. Utility of dynamic susceptibility contrast perfusion-weighted MR imaging and ¹¹C-methionine PET/CT for differentiation of tumor recurrence from radiation injury in patients with high-grade gliomas[J]. American Journal of Neuroradiology, 2019, 40(2):253-259.
[17] 王宁, 印弘, 康晓伟, 等. DCE-MRI定量参数与脑胶质瘤Ki-67标记指数的相关性分析[J]. 放射学实践, 2019, 34(4):417-421.
[18] 谢佳培, 肖亮. 功能磁共振成像技术与Ki-67标记指数对脑胶质瘤恶性度评估的研究进展[J]. 磁共振成像, 2020, 11(6):462-465.
[19] 贾中正, 蒋佳珅, 沈丹丹, 等. 动态对比增强磁共振成像在脑胶质瘤患者瘤细胞增殖定量评估中的应用[J]. 山东医药, 2018, 58(39):17-20.